What is the Fiscal Year for Polaryx Therapeutics?
Date: November 14, 2026
Polaryx Therapeutics's current fiscal year starts on January 1, 2026, and ends on December 31, 2026. Their current quarter is Q4, which ends on December 31, 2026.
Current Fiscal Year Overview
Fiscal Year Start
January 1, 2026
Fiscal Year End
December 31, 2026
Current Quarter
Q4
Current Quarter End
December 31, 2026
Quarterly Breakdown
Q1
Jan 1, 2026 – Mar 31, 2026
Q2
Apr 1, 2026 – Jun 30, 2026
Q3
Jul 1, 2026 – Sep 30, 2026
Q4
Oct 1, 2026 – Dec 31, 2026
Company Information
Headquarters
Paramus, New Jersey, United States
Industry
Healthcare, Biotechnology Research Services
Stock Symbol
PLYX
Website
https://polaryx.comDescription
Polaryx Therapeutics’ mission is to meet the large unmet need and accelerate the availability of treatments for patients and families living with lysosomal storage disorders (LSDs). Our pipeline is comprised of uniquely formulated refocused drugs, New Chemical Entities (NCE), and gene therapy candidates to treat these diseases. There is an urgent need for novel therapeutic interventions for LSDs, including Neuronal Ceroid Lipofuscinosis, Krabbe Disease, Sandhoff Disease, and Niemann-Pick Type A / B Diseases. Polaryx was founded in 2014 with the singular aim of addressing these unmet needs with a strong scientific basis and patient-friendly routes of administration.
Use Salesmotion for Account Data and Insights
Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like Polaryx Therapeutics and uncover key business information that drives smarter conversations.
Book a demo today to strengthen your sales strategy with powerful data and actionable insights.